Voyager Therapeutics Statistics
Share Statistics
Voyager Therapeutics has 54.63M shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 54.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.10M |
| Failed to Deliver (FTD) Shares | 3.13K |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 2.53M, so 4.63% of the outstanding shares have been sold short.
| Short Interest | 2.53M |
| Short % of Shares Out | 4.63% |
| Short % of Float | 5.61% |
| Short Ratio (days to cover) | 4.71 |
Valuation Ratios
The PE ratio is 2.74 and the forward PE ratio is -4.22.
| PE Ratio | 2.74 |
| Forward PE | -4.22 |
| PS Ratio | 1.45 |
| Forward PS | 4.1 |
| PB Ratio | 1.54 |
| P/FCF Ratio | 4.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Voyager Therapeutics Inc. has an Enterprise Value (EV) of 314.59M.
| EV / Earnings | 2.38 |
| EV / Sales | 1.26 |
| EV / EBITDA | 2.49 |
| EV / EBIT | 2.58 |
| EV / FCF | 4.21 |
Financial Position
The company has a current ratio of 4.96, with a Debt / Equity ratio of 0.
| Current Ratio | 4.96 |
| Quick Ratio | 4.96 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.56% and return on capital (ROIC) is 47.05%.
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 0.38% |
| Return on Capital (ROIC) | 47.05% |
| Revenue Per Employee | 1.54M |
| Profits Per Employee | 816.85K |
| Employee Count | 162 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.41M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -33.15% in the last 52 weeks. The beta is 0.89, so Voyager Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | -33.15% |
| 50-Day Moving Average | 6.26 |
| 200-Day Moving Average | 7.4 |
| Relative Strength Index (RSI) | 49.73 |
| Average Volume (20 Days) | 548.48K |
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 250.01M and earned 132.33M in profits. Earnings per share was 3.08.
| Revenue | 250.01M |
| Gross Profit | 245.57M |
| Operating Income | 122.01M |
| Net Income | 132.33M |
| EBITDA | 126.45M |
| EBIT | 122.01M |
| Earnings Per Share (EPS) | 3.08 |
Balance Sheet
The company has 68.80M in cash and 20.29M in debt, giving a net cash position of 48.51M.
| Cash & Cash Equivalents | 68.80M |
| Total Debt | 20.29M |
| Net Cash | 48.51M |
| Retained Earnings | -261.18M |
| Total Assets | 426.04M |
| Working Capital | 329.23M |
Cash Flow
In the last 12 months, operating cash flow was 77.92M and capital expenditures -3.26M, giving a free cash flow of 74.66M.
| Operating Cash Flow | 77.92M |
| Capital Expenditures | -3.26M |
| Free Cash Flow | 74.66M |
| FCF Per Share | 1.74 |
Margins
Gross margin is 9.82K%, with operating and profit margins of 4.88K% and 5.29K%.
| Gross Margin | 9.82K% |
| Operating Margin | 4.88K% |
| Pretax Margin | 5.35K% |
| Profit Margin | 5.29K% |
| EBITDA Margin | 50.58% |
| EBIT Margin | 48.8% |
| FCF Margin | 29.86% |
Dividends & Yields
VYGR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 51.94% |
| FCF Yield | 23.05% |
Analyst Forecast
The average price target for VYGR is $15, which is 153% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 153% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 5 |